Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States
Seyed M. Moghadas, Affan Shoukat, Carolyn E. Bawden, et al.
Clinical Infectious Diseases (2023) Vol. 78, Iss. 5, pp. 1328-1335
Open Access | Times Cited: 18

Showing 18 citing articles:

Public Health Impact of the Adjuvanted RSVPreF3 Vaccine for Respiratory Syncytial Virus Prevention Among Older Adults in the United States
Daniel Molnar, Elizabeth M. La, Frederik Verelst, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 4, pp. 827-844
Open Access | Times Cited: 12
Respiratory syncytial virus infections in adults: a narrative review
Joanne Wildenbeest, David M. Lowe, Joseph F. Standing, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 10, pp. 822-836
Closed Access | Times Cited: 8
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access
Jonne Terstappen, Sarah F Hak, Anant Bhan, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 12, pp. e747-e761
Closed Access | Times Cited: 5
Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults
Zhanwei Du, Abhishek Pandey, Seyed M. Moghadas, et al.
Nature Medicine (2025)
Open Access
Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis
Xiao Li, Lander Willem, Caroline Klint Johannesen, et al.
BMC Medicine (2025) Vol. 23, Iss. 1
Open Access
Respiratory Syncytial Virus Vaccines: Analysis of the Pre-Marketing Clinical Trial for Immunogenicity in the Population over 50 Years of Age
Georgios Papazisis, Xanthippi Topalidou, Georgia Gioula, et al.
(2024)
Open Access | Times Cited: 2
Respiratory Syncytial Virus Vaccines: Analysis of Pre-Marketing Clinical Trials for Immunogenicity in the Population over 50 Years of Age
Georgios Papazisis, Xanthippi Topalidou, Georgia Gioula, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 353-353
Open Access | Times Cited: 2
RSV Infection in Refugees and Asylum Seekers: A Systematic Review and Meta-Analysis
Matteo Riccò, Silvia Corrado, Marco Bottazzoli, et al.
Epidemiologia (2024) Vol. 5, Iss. 2, pp. 221-249
Open Access | Times Cited: 1
Efficacy of anti-RSV vaccination in preventing respiratory syncytial virus disease and severe illness in older adults: a systematic review of randomized controlled trials
Ana Moreira, Ana Beatriz Ribeiro, Inês Oliveira, et al.
European Geriatric Medicine (2024)
Closed Access | Times Cited: 1
Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States
Elizabeth M. La, James E. Graham, David Singer, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Integrated untargeted and targeted lipidomics discovers LPE 16:0 as a protector against respiratory syncytial virus infection
Bin Yang, Chen Shi, Yu Tang, et al.
Journal of Pharmaceutical and Biomedical Analysis (2024) Vol. 250, pp. 116399-116399
Closed Access
Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice
Guangxu Ma, Zeping Xu, Chinyu Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece
George Gourzoulidis, C. Tzanetakos, Argyro Solakidi, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1232-1232
Open Access
Prevention of respiratory syncytial virus from 1991 to 2024: a systematic review and bibliometrics analysis
Xue Li, Xia Yu, Z. Z. Du, et al.
Translational Pediatrics (2024) Vol. 13, Iss. 10, pp. 1858-1869
Open Access

Giovanna Elisa Calabrò, Caterina Rizzo, Alexander Domnich, et al.
PubMed (2024) Vol. 65, Iss. 2 Suppl 1, pp. E1-E159
Closed Access
Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options
Matteo Riccò, Bahaa Abu-Raya, Giancarlo Icardi, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1317-1317
Open Access
Respiratory syncytial virus vaccination among US adults aged ≥60 years
Xiaozhen Geng, Wenjun Wang
Frontiers in Immunology (2024) Vol. 15
Open Access
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany
Ahuva Averin, Bennet Huebbe, Mark Atwood, et al.
Expert Review of Vaccines (2024) Vol. 24, Iss. 1, pp. 1-10
Open Access
From setbacks to success: lessons from the journey of RSV vaccine development
Victor M. Cnossen, Rogier P. van Leeuwen, Natalie I Mazur, et al.
Therapeutic Advances in Vaccines and Immunotherapy (2024) Vol. 12
Open Access
Page 1

Scroll to top